Published in Am J Transl Res on November 15, 2016
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer (2007) 10.20
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Lipid metabolism in cancer. FEBS J (2012) 3.42
FXR, a multipurpose nuclear receptor. Trends Biochem Sci (2006) 1.85
Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol (2013) 1.60
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res (2013) 1.46
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression. Cancer Res (2006) 1.31
Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway. Oncogene (2000) 1.11
Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression. Mol Endocrinol (2012) 1.08
Impact of bile acids on the growth of human cholangiocarcinoma via FXR. J Hematol Oncol (2011) 1.03
Characterization of enantiomeric bile acid-induced apoptosis in colon cancer cell lines. J Biol Chem (2008) 1.01
Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene (2011) 0.98
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget (2014) 0.92
Future of bisphosphonates and denosumab for men with advanced prostate cancer. Cancer Manag Res (2014) 0.86
SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol (2014) 0.85
Activation of free fatty acid receptor 1 improves hepatic steatosis through a p38-dependent pathway. J Mol Endocrinol (2014) 0.80
Activation of the Farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential. Cancer Lett (2015) 0.79
Farnesoid X receptor inhibits LNcaP cell proliferation via the upregulation of PTEN. Exp Ther Med (2014) 0.79